Page not found

×

Warning message

Your search used too many AND/OR expressions. Only the first 7 terms were included in this search.

Search results

  1. Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial

    ... license and a research collaboration agreement for two novel series of M4 receptor modulator compounds, including NMRA-266, in  ... by Conn and Lindsley, NMRA-266 was found to be highly selective to the M4 receptor, the area of the brain that regulates ... collaboration was facilitated by the   Center for Technology Transfer and Commercialization . Vanderbilt researchers who ...

    sommers - 01/17/2024 - 10:08am

  2. Rethinking drug efficacy: research aims to improve drug development

    ... Postdoctoral Fellow in 2023, are developing a startup with technology that will allow drug developers to test the impact of ... altering the current drug development procedures, the technology has potential to facilitate the creation of entirely novel drug categories in the future,” Neuert said. “It also enables the ...

    sommers - 03/11/2024 - 8:54am

  3. mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

    ... promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at ... Then only known competition is one dual mGlu2/3 NAM compound from Roche (decoglurant) is in the clinic, Phase II studies for ...

    cttc_admin - 01/23/2024 - 4:42pm

  4. Innovation Catalyst Fund announces eight inaugural awardees; next round submission deadline is April 15

    ... Cybele Raver and Vice Chancellor for Finance and Information Technology Brett Sweet, received 24 submissions and will provide pre-seed ... professor of chemical and biomolecular engineering: “Novel Hydrogel to Improve and Restore Blood Flow to Bone Tissues Through ...

    sommers - 02/13/2024 - 10:43am

  5. Vanderbilt inks collaboration with Neumora Therapeutics, Inc to continue development of investigational treatment for neuropsychiatric disorders

    ... “We are excited to collaborate with Neumora to advance our novel M4 receptor PAM program,” said Lindsley, also a University Professor ... Thomas Utley, senior licensing officer at the  Center for Technology Transfer and Commercialization . “The team that Neumora has put ...

    sommers - 05/06/2022 - 10:50am

  6. Ten Vanderbilt technologies earn patent protection

    ...       Antibodies to TIP-1 9,738,636       Fused heterocyclic compounds as selective BMP inhibitors 9,737,364      ...

    steelmk - 09/01/2017 - 3:35pm

  7. La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors

    ... led a dedicated research team focused on discovering highly selective, small-molecule kinase inhibitors designed to selectively block ... work hard to translate their pioneering discoveries into novel treatments for patients in need.” About La Jolla ...

    steelmk - 10/02/2015 - 10:45am

  8. ThermoFisher Scientific - Research Interest Areas

    ... run on Qubit platform; low-cost cell counting technologies; novel bioconjugation technologies Cell Analysis Instruments ... analysis of recombinant protein quality; rapid bioburden technology; bioprocess data analytics; technologies for new biotherapeutic ...

    cttc_admin - 01/30/2024 - 12:26pm

  9. Novel anti-platelet therapy for treatment of thrombosis, cardiovascular disease, and cerebrovascular injury

    Technology Description Cardiovascular disease remains one of the ... thrombosis. Vanderbilt researchers have recently developed novel PAR4 antagonists with potential benefits for patients that minimize ... innovative PAR4-specific antagonists based on the MLPCN tool compound ML354. Over 300 analogs with vastly improved drug profiles have been ...

    cttc_admin - 01/23/2024 - 1:42pm

  10. Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

    ... promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at ... compared to the mGlu2 action, the group has developed a Tool compound. This mGlu3 NAM Tool Compound, used for proof of concept studies, has ...

    cttc_admin - 01/23/2024 - 4:43pm